By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.